CGTLive®’s Weekly Rewind – August 9, 2024

August 9, 2024

By CGTLive Staff

News

Article

Review top news and interview highlights from the week ending August 9, 2024.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Indapta to Evaluate g-NK Therapy in Trial for Progressive Multiple Sclerosis

The trial evaluating the safety and tolerability of IDP-023 will be led by Stanford and UCSF.

2. Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy

The cofounder and chief science officer of Longeveron discussed working to show potential benefits in a follow-up phase 3 trial.

3. FDA Modifies CAR-T Risk Strategies to Lower Healthcare Burden

A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.

4. David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development

The chief medical officer at Creyon Bio discussed findings from a treated patient with a TNP02 missense mutation.

5. Pivotal Bria-IMT Trial Hopes to Support BLA for Advanced Metastatic Breast Cancer

BriaCell initiated the pivotal phase 3 BRIA-ABC trial in October 2023.

Recent Videos

Tami John, MD

Tami John, MD

Tami John, MD

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Related Content

Tami John, MD

β-Thalassemia Gene Therapy in the Context of the Broader World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, emphasized the need to build community among patients with TDT.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Tami John, MD

Barriers to Access for Gene Therapy in β-Thalassemia

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, also provided background about the current state of care in TDT.

Related Content

Tami John, MD

β-Thalassemia Gene Therapy in the Context of the Broader World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, emphasized the need to build community among patients with TDT.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Tami John, MD

Barriers to Access for Gene Therapy in β-Thalassemia

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, also provided background about the current state of care in TDT.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.